Trial Profile
Multicenter open-label, phase IIB study with 0.5 mg / day Entecavir (BARACLUDE ) in patients with positive HBsAg solid or hematologic malignancies undergoing chemotherapy (ChemET) (ChemET).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Dec 2012
Price :
$35
*
At a glance
- Drugs Entecavir (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms ChemET
- 06 Aug 2011 New trial record